Hepatitis B vaccination targeted at behavioural risk groups in the Netherlands: Does it work?

Vaccine

Volumn 27, Issue 27, 2009, Pages 3530-3535

  van Houdt, R ^a   Koedijk, F D H ^c   Bruisten, S M ^a,b   Coul, E L M Op de ^c   Heijnen, M L A ^c,d   Waldhober, Q ^d   Veldhuijzen, I K ^e   Richardus, J H ^e,f   Schutten, M ^f   van Doornum, G J J ^f   de Man, R A ^f   Hahne S J ^c   Coutinho, R A ^b,c   Boot, H J ^c  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d Paediatric Association of the Netherlands   (Netherlands)

^e Public Health Service of the Rotterdam Region   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hepatitis B; Molecular epidemiology; Risk groups; Targeted vaccination

Indexed keywords

HEPATITIS B VACCINE;

ADULT; ARTICLE; DISEASE TRANSMISSION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; NETHERLANDS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION; SEXUAL INTERCOURSE; VACCINATION;

ADULT; FEMALE; GENOTYPE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; NETHERLANDS; VACCINATION;

EID: 67349272019     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.072     Document Type: Article

References (23)

1. WHO. Hepatitis B fact sheet 204. http://www.who.int/mediacentre/factsheets/fs204/en/index.html [accessed February, 11, 2008].
2. Marschall T., Kretzschmar M., Mangen M.J.J., and Schalm S. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. Eur J Gastroenterol Hepatol 20 (2008) 1214-1225
3. Van Damme P.F., and Vorsters A. Hepatitis B control in Europe by universal vaccination programs: the situation in 2001. J Med Virol 67 (2002) 433-439
4. Van Steenbergen J.E., and The Working Group Vaccination High-Risk Groups Hepatitis B for the Netherlands. Results of an enhanced-outreach program of hepatitis B vaccination in the Netherlands (1998-2000) among men who have sex with men, hard drug users, sex workers, and heterosexual persons with multiple partners. J Hepatol 37 (2002) 507-513
5. Van Houdt R., Sonder G.J., Dukers N.H., Bovee L.P., Van den Hoek J.A., Coutinho R.A., et al. Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlands. Vaccine 25 (2007) 2698-2705
6. Bakker F., and Vanwesenbeeck I. Seksuele gezondheid in Nederland 2006 (2006), Eburon, Delft
7. Van der Helm T., and Van Mens L. Mobility in prostitution in the Netherlands. EUROPAP-TAMPEP (1999)
8. Smit F., Van Laar M., and Wiessing L. Estimating problem drug use prevalence at national level: comparison of three methods. Drugs: Education Prevention Policy 13 (2006) 109-120
9. Op de Coul E.L., Van Sighem A.I., and Van de Laar M.J. National estimate of people living with HIV/AIDS in 2005 in the Netherlands. Infectieziekten Bull 17 (2006) 398-403
10. De Wit GA, Kretzschmar MEE, Smits LJM, Struijs JN, Postma MJ, Van de Laar MJW, et al., Cost-effectiveness of national hepatitis B vaccination: Interim report. Bilthoven: National institute for public health and the environment (RIVM) 2000; report 403505 004.
11. Van Houdt R., Bruisten S.M., Koedijk F.D., Dukers N.H., Op de Coul E.L., Mostert M.C., et al. Molecular epidemiology of acute hepatitis B in the Netherlands in 2004: nationwide survey. J Med Virol 79 (2007) 895-901
12. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41 (1999) 95-98
13. Kumar S., Tamura K., and Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 5 (2004) 150-163
14. Fisker N.F., Pedersen C.F., Lange M.F., Nguyen N.T., Nguyen K.T., Georgsen J., et al. Molecular epidemiology of hepatitis B virus infections in Denmark. J Clin Virol 31 (2004) 46-52
15. Hahne S., Ramsay M., Balogun K., Edmunds W.J., and Mortimer P. Incidence and routes of transmission of hepatitis B virus in England and Wales 1995-2000: implications for immunisation policy. J Clin Virol 29 (2004) 211-220
16. Lindenburg C.E., Krol A., Smit C., Buster M.C., Coutinho R.A., and Prins M. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS 20 (2006) 1771-1775
17. Tacke F., Amini-Bavil-Olyaee S., Heim A., Luedde T., Manns M.P., and Trautwein C. Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune competent German patient. J Clin Virol 38 (2007) 353-357
18. De Wit J.B.F., Vet R., Schutten M., and Van Steenbergen J.E. Social-cognitive determinants of vaccination behaviour against hepatitis B: an assessment among men who have sex with men. Prevent Med 40 (2005) 795-802
19. Schutten M., De Wit J.B.F., and Van Steenbergen J.E. Why do gay men want to be vaccinated against hepatitis B? An assessment of psychosocial determinants of vaccination intention. Int J STD AIDS 13 (2002) 86-90
20. Hospers H.J., Dorfler T.T., Zuilhof W., and Nijman A.M. Schorer monitor 2007 (2007), Schorer, Amsterdam ISBN 978-90-7334-132-9
21. Heron L., Selnikova O., Moiseieva A., Van Damme P., Van der Wielen M., Levie K., et al. Immunogenicity, reactogenicity, and safety of two-dose versus three-dose (standard care) hepatitis B immunization of healthy adolescents ages 11-15 years: a randomized control trial. Vaccine 25 (2007) 2817-2822
22. Van den Broek IV, Koedijk FD, Van Veen MG, Op de Coul EL, Van Sighem AI, Van der Sande MA. Sexually transmitted infections, including HIV, in the Netherlands in 2007. Report 210261 004. National Institute for Public Health and the Environment (RIVM); 2008.
23. Kretzschmar M., Mangen M.J., Van de Laar M., and De Wit A. Model based analysis of hepatitis B vaccination strategies in the Netherlands. Vaccine 27 (2009) 1254-1260